Beta Bionics (NASDAQ:BBNX) Downgraded by Bank of America to “Neutral”

Bank of America downgraded shares of Beta Bionics (NASDAQ:BBNX) from a buy rating to a neutral rating in a research report report published on Friday morning, Marketbeat reports.

Several other research analysts have also recently weighed in on the stock. Robert W. Baird set a $28.00 price target on shares of Beta Bionics in a research report on Tuesday, December 16th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Beta Bionics in a report on Monday, December 29th. Lake Street Capital restated a “buy” rating and set a $35.00 price target on shares of Beta Bionics in a report on Wednesday, October 29th. Wall Street Zen upgraded Beta Bionics from a “strong sell” rating to a “hold” rating in a report on Saturday, November 1st. Finally, The Goldman Sachs Group increased their price objective on Beta Bionics from $26.00 to $33.00 and gave the stock a “buy” rating in a research report on Wednesday, October 29th. One research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Beta Bionics currently has an average rating of “Moderate Buy” and a consensus price target of $30.20.

Beta Bionics Price Performance

BBNX stock opened at $20.14 on Friday. Beta Bionics has a 1 year low of $8.89 and a 1 year high of $32.71. The firm has a market capitalization of $886.76 million and a PE ratio of -4.61. The business has a 50 day simple moving average of $29.28 and a 200-day simple moving average of $22.27.

Beta Bionics (NASDAQ:BBNX) last announced its quarterly earnings data on Tuesday, October 28th. The company reported ($0.33) EPS for the quarter, topping analysts’ consensus estimates of ($0.45) by $0.12. The firm had revenue of $27.25 million for the quarter, compared to the consensus estimate of $23.92 million. Beta Bionics had a negative return on equity of 35.72% and a negative net margin of 87.89%.

Insider Activity at Beta Bionics

In related news, Director Adam Lezack sold 1,406 shares of the stock in a transaction dated Friday, October 31st. The stock was sold at an average price of $26.87, for a total transaction of $37,779.22. Following the transaction, the director owned 9,841 shares of the company’s stock, valued at approximately $264,427.67. This represents a 12.50% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Mike Mensinger sold 7,800 shares of the firm’s stock in a transaction dated Friday, January 2nd. The shares were sold at an average price of $29.61, for a total value of $230,958.00. Following the transaction, the insider owned 82,952 shares of the company’s stock, valued at $2,456,208.72. This trade represents a 8.59% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last 90 days, insiders sold 35,302 shares of company stock worth $1,036,449.

Institutional Trading of Beta Bionics

Several hedge funds have recently made changes to their positions in the business. GPS Wealth Strategies Group LLC boosted its stake in shares of Beta Bionics by 45.0% in the third quarter. GPS Wealth Strategies Group LLC now owns 1,450 shares of the company’s stock valued at $29,000 after purchasing an additional 450 shares during the period. EverSource Wealth Advisors LLC grew its stake in shares of Beta Bionics by 203.6% in the third quarter. EverSource Wealth Advisors LLC now owns 2,377 shares of the company’s stock worth $47,000 after acquiring an additional 1,594 shares in the last quarter. Verition Fund Management LLC grew its stake in shares of Beta Bionics by 4.0% in the third quarter. Verition Fund Management LLC now owns 47,299 shares of the company’s stock worth $940,000 after acquiring an additional 1,823 shares in the last quarter. Ameritas Investment Partners Inc. increased its position in shares of Beta Bionics by 139.1% during the third quarter. Ameritas Investment Partners Inc. now owns 3,202 shares of the company’s stock worth $64,000 after acquiring an additional 1,863 shares during the period. Finally, The Manufacturers Life Insurance Company raised its stake in shares of Beta Bionics by 10.3% in the second quarter. The Manufacturers Life Insurance Company now owns 23,558 shares of the company’s stock valued at $343,000 after acquiring an additional 2,205 shares in the last quarter.

Key Headlines Impacting Beta Bionics

Here are the key news stories impacting Beta Bionics this week:

• Positive Sentiment: Preliminary Q4 topline and revenue guidance: Beta Bionics announced preliminary, unaudited Q4 2025 topline growth and issued revenue guidance of roughly $32.0M versus a ~ $29.0M consensus, signaling stronger-than-expected sales momentum. GlobeNewswire – Q4 Topline Results
• Neutral Sentiment: Company release is preliminary/unaudited and EPS guidance was not specified — investors must await audited results and detailed metrics to confirm margin and profitability trends. Finanznachrichten – Preliminary Results
• Negative Sentiment: Deceleration in new patient starts: Reports highlighted a slowdown in new patient onboarding for the iLet system, which traders flagged as a demand-growth warning and a primary reason shares tumbled. Investing.com – New Patient Starts Slow
• Negative Sentiment: Analyst downgrades and valuation concerns: Multiple analysts moved to neutral/hold citing a premium valuation alongside slowing new-patient growth (Bank of America shifted to Neutral with a ~$28 PT), increasing selling pressure. DrugDeliveryBusiness – Analyst Downgrades TipRanks – Valuation & Growth
• Negative Sentiment: Insider selling: A named insider sold shares in early January (disclosed filings show several recent sales), which can weigh on sentiment when combined with downgrades and slowing customer adds. MarketBeat – Insider Trades

Beta Bionics Company Profile

Beta Bionics, a clinical-stage medical device company headquartered in Boston, Massachusetts, is focused on revolutionizing the management of type 1 diabetes through automated insulin delivery solutions. The company’s flagship product, the iLet Bionic Pancreas system, is designed to simplify glycemic control by automatically adjusting insulin dosing in response to continuous glucose monitoring data. By integrating advanced algorithmic control with wearable infusion pumps, the iLet aims to reduce the daily burden of diabetes management and improve clinical outcomes for patients.

At the core of Beta Bionics’ offering is its proprietary bionic pancreas software, which can operate in both insulin-only and dual‐hormone modes.